Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Acta Neurologica Scandinavica

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1034/j.1600-0404.2002.1o174.xPMID 11939936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Parkinson's disease: Problems with a progressing disease

  2005cited by this paper
• Twelve‐month safety of entacapone in patients with Parkinson’s disease

  2001cited by this paper
• Neutralizing and binding anti‐interferon‐β (IFN‐β) antibodies. A comparison between IFN‐β‐1a and IFN‐β‐1b treatment in multiple sclerosis

  2000cited by this paper
• Levodopa motor complications in Parkinson's disease.

  2000cited by this paper
• The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

  2000cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Health-Related Quality-of-Life Measurement in Patients with Parkinson’s Disease

  1999cited by this paper
• Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

  1999cited by this paper
• COMT Inhibitors in Parkinson's Disease

  1999cited by this paper
• Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

  1998cited by this paper
• Costs of drug treatment in Parkinson's disease

  1998cited by this paper
• Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon

  1998cited by this paper
• Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

  1997cited by this paper
• Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment

  1997cited by this paper
• Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

  1997cited by this paper
• Tolcapone in stable Parkinson's disease

  1997cited by this paper
• Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial

  1997cited by this paper
• Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• Entacapone in combination with standard or controlled‐release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease

  1995cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994cited by this paper
• General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.

  1994cited by this paper
• Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

  1992cited by this paper
• The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials

  1991cited by this paper
• New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

  1989cited by this paper
• Low‐dose L‐dopa therapy in Parkinson's disease

  1986cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper

• “Unfolding Parkinson’s Disease Through the Microbiome-Gut-Brain Axis”

  2026cites this paper
• Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial

  2025cites this paper
• Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson’s disease experiencing wearing off

  2025cites this paper
• Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

  2025cites this paper
• Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.

  2025cites this paper
• Treatment strategies for motor fluctuations in Parkinson’s disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America

  2025cites this paper
• The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson’s Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On

  2024cites this paper
• Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.

  2024cites this paper
• Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

  2023cites this paper
• Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs

  2023cites this paper
• Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis

  2023cites this paper
• Importance of time to ON versus wearing OFF in total daily OFF time experienced by patients with Parkinson's disease.

  2023cites this paper
• Therapieansätze für das fortgeschrittene idiopathische Parkinson-Syndrom

  2023cites this paper
• Catechol‐O‐methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson's disease

  2023cites this paper
• Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.

  2022cites this paper
• Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

  2022cites this paper
• Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?

  2022cites this paper
• The Clinical Pharmacology of Entacapone (Comtan®) From the Food and Drug Administration (FDA) Reviewer.

  2022cites this paper
• What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?

  2022cites this paper
• COMT Inhibitors in the Management of Parkinson’s Disease

  2022cites this paper
• Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone

  2021cites this paper
• Entacapone - Another Parkinson's medication associated with lymphocytic colitis.

  2021cites this paper
• Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis

  2021cites this paper
• Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

  2021cites this paper
• Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease

  2021cites this paper
• Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease

  2020cites this paper
• Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysis

  2020cites this paper
• Istradefylline: a novel drug for ‘off’ episodes in Parkinson’s disease

  2020cites this paper
• Guidelines for the Use of Parkinsonian Drugs (in USA)

  2020cites this paper
• On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease

  2020cites this paper
• Pharmacotherapeutic Strategies to Treat or Prevent OFF Episodes in Adults with Parkinson's disease

  2020cites this paper
• Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease

  2020cites this paper
• Medical Management and Prevention of Motor Complications in Parkinson’s Disease

  2020cites this paper
• Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes

  2019cites this paper
• Young-onset Parkinson's disease: Its unique features and their impact on quality of life.

  2019cites this paper
• Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review

  2019cites this paper
• In this issue

  2018cites this paper
• Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review

  2018cites this paper
• Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology

  2018cites this paper
• Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease

  2018cites this paper
• Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine

  2018cites this paper
• A Computer-Assisted Systematic Search for Melatonin Derivatives with High Potential as Antioxidants

  2018cites this paper
• Opicapone for the treatment of Parkinson’s disease

  2017cites this paper
• Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison

  2017cites this paper
• Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson’s Disease with Motor Fluctuation: A Systematic Meta-Analysis

  2017cites this paper
• Old and new challenges in Parkinson's disease therapeutics

  2017cites this paper
• Treatment for Dementia: Learning from Breakthroughs for Other Conditions.

  2016cites this paper
• Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.

  2016cites this paper
• Parkinsonism and Related Disorders

  2016cites this paper
• A review of current and novel levodopa formulations for the treatment of Parkinson's disease.

  2016cites this paper
• Improving l‐dopa therapy: The development of enzyme inhibitors

  2015influential citation
• Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

  2015cites this paper
• Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

  2015cites this paper
• Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity.

  2015cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• The efficacy of Levodopa+DDC inhibitor+Entacapone versus Levodopa+DDC inhibitor+Placebo in Parkinson's disease: an intervention review

  2015cites this paper
• Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off

  2015cites this paper
• Meta-analysis of Placebo-controlled Clinical Trials of Safinamide and Entacapone as Add-on Therapy to Levodopa in the Treatment of Parkinson's Disease

  2015cites this paper
• Medikamentöse Therapie des fortgeschrittenen Morbus Parkinson

  2014cites this paper
• Multifunctional approach of L-Dopa induced dyskinesia pathophysiology in Parkinson’s disease : from the striatum to the whole brain

  2014cites this paper
• Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease

  2014cites this paper
• Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease

  2014cites this paper
• Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.

  2014cites this paper
• Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease

  2014cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease

  2014cites this paper
• Pooled analysis of phase III with entacapone in Parkinson's disease

  2014cites this paper
• Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque

  2013cites this paper
• Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

  2013cites this paper
• Catechol-O-methyltransferase inhibitors

  2013cites this paper
• Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson’s Disease, and Levodopa Efficacy

  2013cites this paper
• Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications

  2013cites this paper
• IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.

  2013cites this paper
• Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone

  2012cites this paper
• Psychiatric, nonmotor aspects of Parkinson's disease.

  2012cites this paper
• Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials

  2012cites this paper
• The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations

  2012cites this paper
• Perampanel in Parkinson Disease Fluctuations: A Double-Blind Randomized Trial With Placebo and Entacapone

  2012cites this paper
• [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].

  2012cites this paper
• Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.

  2012cites this paper
• A Systematic Review of Catechol-O-Methyltransferase Inhibitors: Efficacy and Safety in Clinical Practice

  2012cites this paper
• Updates in the medical management of Parkinson disease

  2012cites this paper
• Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.

  2011cites this paper
• Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off

  2011cites this paper
• Deep Brain Stimulation for Early‐Stage Parkinson's Disease: An Illustrative Case

  2011cites this paper
• Strategies for Parkinson’s disease care: prevention and management of motor fluctuations

  2011cites this paper
• Entacapone promotes cAMP‐dependent colonic Cl− secretion in rats

  2011cites this paper
• [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].

  2011cites this paper
• No correlation between COMT genotype and entacapone benefi ts in Parkinson ’ s disease

  2011cites this paper
• Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

  2011cites this paper
• Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

  2011cites this paper
• No correlation between COMT genotype and entacapone benefits in Parkinson's disease

  2011cites this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cites this paper
• Toxicology and safety of COMT inhibitors.

  2010cites this paper
• Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

  2010cites this paper
• Entacapone

  2010cites this paper
• Current management of Parkinson's disease.

  2010cites this paper
• Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

  2010cites this paper
• Therapie psychischer Störungen bei Morbus Parkinson

  2010cites this paper
• The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease

  2010cites this paper